Completed first tranche of 75% acquisition in Apnar Pharma

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.7%Reaction day

₹787.10

prior close

₹790.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-1.3%+4.0% vs market

Pharmaceuticals peers, median of 158sector-0.8%+3.4% vs sector

On the reaction day the stock moved 4.0 pts more than Nifty Microcap 250 and 3.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.6

10m

-2.4

15m

-2.3

30m

-2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.7-1.3+4.0-0.8+3.4

Next day

+1.8-4.0+5.8-3.1+5.0

+6.6-4.8+11.3-4.1+10.6

+6.1-3.3+9.4-3.0+9.1

+1.8-5.3+7.1-4.4+6.2

+1.5-5.2+6.7-4.7+6.3

-1.5-3.7+2.1-4.1+2.5

15d

+5.3+3.6+1.7-1.1+6.4

+3.0+0.1+2.9-2.4+5.5

-6.9-8.9+2.0-10.1+3.1

+16.9+3.2+13.7-1.1+18.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Senores Pharmaceuticals has completed the first tranche of its acquisition of Apnar Pharma Private Limited, acquiring 75 percent stake (56,63,804 equity shares) for about Rs 11.46 crore. This is part of the full 100 percent acquisition announced earlier via a Share Purchase Agreement in two tranches. The remaining 25 percent stake is expected to be acquired by Q2 of FY 2027, which will make Apnar a wholly-owned subsidiary.

Likely market impact

Expands the companys business via acquisition; balance 25 percent stake buyout expected by Q2 FY27 to make Apnar a fully-owned subsidiary.